Association of Cannabis Use During Adolescence With Neurodevelopment Matthew D. Albaugh, PhD; Jonatan Ottino-Gonzalez, PhD; Amanda Sidwell, BS; Claude Lepage, PhD; Anthony Juliano, PsyD; Max M. Owens, PhD; Bader Chaarani, PhD; Philip Spechler, PhD; Nicholas Fontaine, BS; Pierre Rioux, MSc; Lindsay Lewis, PhD; Seun Jeon, PhD; Alan Evans, PhD; Deepak D’Souza, MD; Rajiv Radhakrishnan, MD; Tobias Banaschewski, MD, PhD; Arun L.W. Bokde, PhD; Erin Burke Quinlan, PhD; Patricia Conrod, PhD; Sylvane Desrivières, PhD; Herta Flor, PhD; Antoine Grigis, PhD; Penny Gowland, PhD; Andreas Heinz, MD, PhD; Bernd Ittermann, PhD; Jean-Luc Martinot,MD, PhD; Marie-Laure Paillère Martinot,MD, PhD; Frauke Nees, PhD; Dimitri Papadopoulos [...]
Lire la suiteLow-Dose Nitrous Oxide Shows Benefit for Resistant Depression Batya Swift Yasgur, MA, LSW Medscape.com, 2021 June 17, 2021 A 1-hour treatment with a low concentration of nitrous oxide, commonly known as "laughing gas," appears to relieve symptoms of treatment-resistant major depression (TRMD), with effects lasting as long as several weeks, new research suggests. In a trial with a crossover design, investigators randomly assigned 28 patients with severe TRMD to receive a single 1-hour inhalation of placebo or nitrous oxide once a month over a 3-month period. Participants received an inhalation of placebo; a 25% concentration of nitrous oxide; and a 50% concentration of nitrous oxide. Sessions were [...]
Lire la suiteCannabis and synaptic reprogramming of the developing brain Anissa Bara, Jacqueline- Marie N. Ferland, Gregory Rompala, Henrietta Szutorisz and Yasmin L. Hurd Nature Reviews | Neuroscience, 2021, https://doi.org/10.1038/s41583-021-00465-5 Abstract Recent years have been transformational in regard to the perception of the health risks and benefits of cannabis with increased acceptance of use. This has unintended neurodevelopmental implications given the increased use of cannabis and the potent levels of Δ9-tetrahydrocannabinol today being consumed by pregnant women, young mothers and teens. In this Review, we provide an overview of the neurobiological effects of cannabinoid exposure during prenatal/perinatal and adolescent periods, in which the endogenous cannabinoid system plays [...]
Lire la suiteContre les stupéfiants, Macron prône l’acharnement thérapeutique 19 avr. 2021 Par Camille Polloni et Ellen Salvi - Mediapart.fr Jadis ouvert à la dépénalisation du cannabis, le chef de l’État se dit aujourd’hui favorable à une politique antidrogues sévère, visant à « harceler les trafiquants et les dealers », mais aussi les usagers. Quitte à s’enfoncer dans une impasse. Du cannabis saisi et photographié à Marseille lors d'une visite de Gérald Darmanin, le 25 février. © Nicolas Tucat/AFP C’est une profession de foi digne d’un ministre de l’intérieur en exercice, promesses et objectifs chiffrés à l’appui, mais le président de la République en est pour une fois [...]
Lire la suiteN° 4173 _____ ASSEMBLÉE NATIONALE CONSTITUTION DU 4 OCTOBRE 1958 QUINZIÈME LÉGISLATURE Enregistré à la Présidence de l’Assemblée nationale le 18 mai 2021. PROPOSITION DE LOI relative à la lutte contre le commerce illégal de drogues, (Renvoyée à la commission des affaires sociales, à défaut de constitution d’une commission spéciale dans les délais prévus par les articles 30 et 31 du Règlement.) présentée par Mesdames et Messieurs Éric COQUEREL, Jean-Félix ACQUAVIVA, Ugo BERNALICIS, Alexis CORBIÈRE, Elsa FAUCILLON, Hubert JULIEN-LAFERRIÈRE, François-Michel LAMBERT, Jean-Baptiste MOREAU, Danièle OBONO, Matthieu ORPHELIN, Richard RAMOS, Jean-Hugues RATENON, Muriel RESSIGUIER, Bénédicte TAURINE, Michèle VICTORY, Patrick VIGNAL, députés. EXPOSÉ DES MOTIFS MESDAMES, MESSIEURS, Cette proposition de loi se donne pour objectif de [...]
Lire la suiteA qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties Rachael L. Sumner, Emme Chacko, Rebecca McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D. Muthukumaraswamy and Frederick Sundram Journal of Psychopharmacology, 2021, 1-16 Doi : 10.1177/0269881121998321 Abstract Background : Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim : The aim of the current study was to explore the [...]
Lire la suiteEffects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease Stephanie Martins de Faria, Daiene de Morais Fabrício, Vitor Tumas, Paula Costa Castro, Moacir Antonelli Ponti, Jaime E.C. Hallak, Antonio W. Zuardi, José Alexandre S. Crippa and Marcos Hortes Nisihara Chagas Journal of Psychopharmacology, 2020, 1–8 doi : 10.1177/0269881119895536 Abstract Background : Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to [...]
Lire la suiteCase in Context : Tourette Syndrome Kirsten MÜLLER-VAHL Cannabis and Cannabinoid Research, 2021, 1-4. doi : 10.1089/can.2021.0005 Dr. Kirsten Müller-Vahl: Mr. Miller,* thank you very much for taking part in this interview. I would like to ask you to first explain how Tourette syndrome has impacted your life and what restrictions you experienced. Miller: The first tics appeared approximately when I was 5 years old. Especially during my childhood, I had more intense vocal tics consisting of different sounds and noises. Later on, I suffered mainly from motor tics such as shaking my head or poking my tongue out. People did not understand why I [...]
Lire la suiteAbsence of Entourage : Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Functional Activity of Δ9-THC at Human CB1 and CB2 Receptors Marina Santiago, Shivani C. Arnold, Iain S., McGregor and Mark Connor Cannabis and Cannabinoid Research, 2019, Vol. 4, No. 3 doi : 10.1089/can.2019.0016 Abstract Introduction: Compounds present in Cannabis sativa such as phytocannabinoids and terpenoids may act in concert to elicit therapeutic effects. Cannabinoids such as Δ9-tetrahydrocannabinol (Δ9-THC) directly activate cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2); however, it is not known if terpenoids present in Cannabis also affect cannabinoid receptor signaling. Therefore, we examined six common terpenoids alone, [...]
Lire la suiteWithin-treatment changes in a novel addiction treatment program using traditional Amazonian medicine David M. O’Shaughnessy , Ilana Berlowitz, Robin Rodd, Zoltán Sarnyai and Frances Quirk Therapeutic Advances in Psychopharmacology, 2021, Vol. 11, 1–18 DOI : 10.1177/2045125320986634 Abstract Aims : The therapeutic use of psychedelics is regaining scientific momentum, but similarly psychoactive ethnobotanical substances have a long history of medical (and other) uses in indigenous contexts. Here we aimed to evaluate patient outcomes in a residential addiction treatment center that employs a novel combination of Western and traditional Amazonian methods. Methods : The study was observational, with repeated measures applied throughout treatment. All tests were administered in [...]
Lire la suite